Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 versus valsartan in heart failure with preserved ejection fraction
NL-OMON35586Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and chronic heart failure (CHF) comparing LCZ696 with valsartan (2 arms). Started Oct 2010; status: active, not recruiting.
02
Drugs
sacubitril + valsartanvalsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on NL-OMON35586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35586.